Skip to main content
. 2020 May 21;8(7):3515–3524. doi: 10.1002/fsn3.1634

Figure 2.

Figure 2

Nobiletin treatment inhibits PKA/CREB pathway. (a) Western bolt analysis of key PKA pathway markers in TCA‐8133 and CAL‐27 cells following treatment with the indicated concentrations of nobiletin for 24 hr. Cells treated with an equal volume of DMSO served as control. (b) TCA‐8113 and CAL‐27 cells were treated with 100 μmol/L nobiletin for 24 hr in the absence or presence of 50 μmol/L Sp‐cAMP, a potent PKA activator, followed by Western blot analysis of proliferation‐related proteins. Cells treated with an equal volume of DMSO served as control. Representative images were taken from three independent experiments. (c) Proliferation of TCA‐8133 and CAL‐27 cells was determined by the Cell Counting Kit‐8 (CCK8) after 24 hr treatment with 100 μmol/L nobiletin in the absence or the presence of 50 μmol/L Sp‐cAMP. Cells treated with equal volume of DMSO served as control. Data from three independent experiments shown as mean ± SD. *, p < .05 compared to control group